TradeFlare's AI research teams analysed HALO on 8 market nights between May 15, 2026 and October 2, 2026. Each row is that night's verdict, the price that day, and how the price actually moved afterwards — wins and misses alike. Nothing is edited after the fact.
| Date | Verdict | Price | Target / stop | 5 days later | 20 days later | Why (that night) |
|---|---|---|---|---|---|---|
| October 2, 2026 | BUY | $106.94 | $112.70 / $90.90 | +0.5% | not yet | The scanner trigger suggests a short-term mean-reversion opportunity. |
| September 25, 2026 | BUY | $115.22 | $132.50 / $97.94 | -3.5% | not yet | The stock is near its 52-week high, suggesting potential for continued momentum. |
| September 23, 2026 | BUY | $115.13 | $132.45 / $97.86 | -1.8% | not yet | The setup is a 52-week breakout, suggesting potential for sustained momentum over a few weeks. |
| September 21, 2026 | BUY | $112.45 | $130.70 / $95.58 | +1.3% | not yet | The stock is breaking out to new highs with strong fundamental and sentiment support, suggesting a sustained move. |
| August 7, 2026 | BUY | $85.76 | $98.97 / $77.18 | -4.3% | +6.9% | The 52-week breakout suggests immediate upward momentum that can be captured over a few weeks. |
| May 19, 2026 | BUY | $67.12 | — / — | -0.1% | -0.2% | Continued strong revenue and earnings growth driven by ENHANZE® drug-delivery technology. |
| May 18, 2026 | BUY | $67.12 | — / — | +1.9% | +3.3% | Continued strong revenue and earnings growth driven by ENHANZE® drug-delivery technology. |
| May 15, 2026 | BUY | $69.21 | — / — | +1.8% | +6.2% | Continued post-earnings drift (PEAD) from strong Q1 earnings beat. |
Prices are daily closes. "Days later" counts trading days from the close on the day of the call. A HOLD is not a recommendation to buy; only published signals are tracked with a target and stop on the public record. How the research works. Updated October 14, 2026. AI-generated research for educational purposes — it can be wrong and is not financial advice.